Scholars Central

Research articlePublished 26 Aug 2021

Docking Molecular Analysis of Potential Drug Paritaprevir against Mycobacterium tuberculosis (Mtb)

Authors: Ivan Vito Ferrari, Paolo Patrizio

Journal of Blood Disorders & Transfusion

Volume 12 · Issue 7 · Pages 1–3

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Mycobacterium tuberculosis (Mtb) is the causative agent of tuberculosis, which kills 1.8 million annually. This is an infectious disease generally affects the lungs, but can also affect other parts of the body. Mtb RNA polymerase (RNAP) is the target of the first-line antituberculosis drug Rifampin (Rif). We report first time a Potential Drug Paritaprevir against with severe infectious disease, by in silico approach, using Auto dock Vina and Auto dock 4 (or MGL Tool), estimated with Pyrx and AM Dock Software, calculating three different important parameters: Binding Affinity (kcal/mol), estimated Ki (in nM units) and Ligand Efficiency (L.E. in kcal/mol). After a selective analysis of over 1000 drugs, processed with Pyrx (a Virtual Screening software for Computational Drug Discovery) in the Ligand Binding site pocket of the protein (ID PDB 5UHB chain C, DNA-directed RNA polymerase subunit beta), we noticed high values of these 3 parameters mentioned above of Paritaprevir, concluding that it could be an excellent candidate drug for this type of infection. Indeed, from the results of Auto dock Vina and Auto dock 4 (or Auto dock 4.2), implemented with lamarckian genetic algorithm, LGA, trough AM Dock Software, This oral drug, approved by FDA in 2014, both by Auto dock Vina and Auto dock Vina 4 has excellent Binding affinity value, ca. -10.00 kcal/ mol, a Ki value 40 nM and Ligand efficiency ca-0.15 kcal/mol. These results are comparable to the drug crystallized in the above-mentioned protein, currently used against TBC.

Subjects

Haematology

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Journal of Blood Disorders & Transfusion.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Blood Disorders & Transfusion
  • SubjectHaematology
  • BylineArticles whose byline prints “Ivan Vito Ferrari”
  • BylineArticles whose byline prints “Paolo Patrizio”